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Abstract
Malignant gliomas are the most common and deadly type of central nervous system tumors. Despite some advances
in treatment, the mean survival time remains only about 1.25 years. Even after surgery, radiotherapy and
chemotherapy, gliomas still have a poor prognosis. Exosomes are the most common type of extracellular vesicles with
a size range of 30 to 100 nm, and can act as carriers of proteins, RNAs, and other bioactive molecules. Exosomes play a
key role in tumorigenesis and resistance to chemotherapy or radiation. Recent evidence has shown that exosomal
microRNAs (miRNAs) can be detected in the extracellular microenvironment, and can also be transferred from cell to
cell via exosome secretion and uptake. Therefore, many recent studies have focused on exosomal miRNAs as important
cellular regulators in various physiological and pathological conditions. A variety of exosomal miRNAs have been
implicated in the initiation and progression of gliomas, by activating and/or inhibiting different signaling pathways.
Exosomal miRNAs could be used as therapeutic agents to modulate different biological processes in gliomas. Exosomal
miRNAs derived from mesenchymal stem cells could also be used for glioma treatment. The present review
summarizes the exosomal miRNAs that have been implicated in the pathogenesis, diagnosis and treatment of gliomas.
Moreover, exosomal proteins could also be involved in glioma pathogenesis. Exosomal miRNAs and proteins could also
serve as non-invasive biomarkers for prognosis and disease monitoring.
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Background
Malignant glioma is the most deadly type of brain cancer
in humans [1]. It is commonly divided into four grades
(I–IV) according to histopathological evaluation. Glioblast-
oma mutiforme (GBM), grade IV glioma, is the most com-
mon and lethal sub-type. Even after the standard treatment
methods, including a combination of surgery with radio-
chemotherapy [2], the prognosis of GBM IV patients is
very poor [3]. According to WHO 2016, conventional
histological examination using H&E-stained sections, re-
mains the initial method of stratification, which determines
the major categories, such as infiltrating glioma, embryonal
tumor or neuronal tumor based on the histology [4]. The
median survival for GBM IV patients is only 15months,
and only 3–5% survive more than 36months [5]. The lack
of a non-invasive monitoring procedure to assess the
effectiveness of GBM treatment is also a bottleneck for
clinical management.
Extracellular vesicles (EVs) are cell membrane-coated
vesicles shed from cells that transport cytoplasmic or
membrane components to nearby cells and can be
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detected in body fluids. EVs contain various components
such as proteins, lipids, DNAs, mRNAs, and various
types of non-coding RNAs [6–8]. Exosomes are a sub-
group of EVs with a size range of 30–100 nm. EVs which
are released by the direct pathway have often been called
“microvesicles”, whereas EVs released by the endocytic
pathway have often been termed “exosomes”. They
mediate signaling pathways between cancer cells and the
other cells in their environment [9, 10].
The transfer of various cargos contained within
exosomes is a critical process to mediate cell-cell com-
munications [11]. Exosomes play a vital role in cancer
because their contents such as microRNAs (miRNAs),
proteins and other physiological compounds vary at
different stages of cancer development [12, 13]. miRNAs
are non-coding single-stranded RNAs with a length of
18–27 nucleotides. They influence various cellular
processes by decreasing the level of translation of their
target mRNAs [14]. Recent studies have shown that
miRNAs conveyed within exosomes can mediate
communication between cancer cells and their milieu
[15–17]. Exosomal miRNAs have been associated with
glioma pathogenesis via activation and/or inhibition of
several signaling pathways. Better understanding of the
role of exosomal miRNAs could contribute to the
discovery and development of new diagnostic and thera-
peutic platforms for glioma. The present review summa-
rizes the different exosomal miRNAs and proteins that
have been reported to be involved in the pathogenesis of
gliomas. We highlight some exosomal miRNAs and
proteins that could be used as diagnostic and therapeutic
biomarkers in glioma.
Exosome biogenesis
The criteria for dividing EVs into subtypes are: a)
physical characteristics of EVs, such as size or density;
b) biochemical composition; or c) descriptions of the
conditions or cells of origin [18]. Based on their size
and biogenesis, EVs can be divided into three types
including: 1) exosomes; 2) microvesicles; and 3) apop-
totic bodies [19, 20]. Exosomes are vesicles with a size
range 30-100 nm [21]. Exosomes are composed of a
common combination of protein and lipid compo-
nents. The composition is derived from the endosomes
from which they originate. The proteins comprise,
tetraspanins (CD9, CD63, CD81 and CD82), multivesi-
cular body related proteins (Alix and Tsg101), heat
shock proteins (Hsp90 and Hsc70), transport proteins
(GTPases, annexins and flotillin), and integrins. The
membrane lipids consist of cholesterol, sphingomyelin
and ceramide [22–24]. The outer surface of exosomes has
many saccharide groups, such as mannose, sialic acid and
glycans. The space between the two sides of the lipid
membrane is enriched in phosphatidyl ethanolamine [23].
The ESCRT (endosomal sorting complexes required
for transport) proteins are involved in exosome gener-
ation, as shown in Fig. 1. The ESCRT protein family is
divided into four subgroups, i.e., ESCRT-0, ESCRT-I,
ESCRT-II, ESCRT-III [26]. These proteins operate in a
sequential manner on the cytosolic endosomal surface,
which leads to ILV formation via stimulating the in-
ward budding of the membrane, followed by fission.
ESCRT-0 launches the endosomal ESCRT pathway by
inducing phosphatidylinositol 3-phosphate to bind to
ubiquitin. Hrs and STAM1/2, both of which are ESCR
T-0 proteins, play an important role in the binding of
the ubiquitinated cargos. The Hrs subunit binds phos-
phatidylinositol 3-phosphate using its FYVE domain,
thereby recruiting ESCRT-0 to pre-MVB endosomes
[27]. An ubiquitin-interacting domain is also found in
ESCRT-I and ESCRT-II, which sort the ubiquitinated
cargos into ILV along with ESCRT-0. The membrane
is consequently invaginated and constricted by ESCR
T-III which is recruited by ESCRT-I and ESCRT-II
[27]. The ubiquitinated cargos of exosomes, which
consist of both cytoplasmic and membrane proteins,
are organized by ESCRT complexes. Exosomal secre-
tion is highly dependent on TSG101, a subunit of
ESCRT-1. MVBs may be triggered by some cargos
without interactions with ESCRT-0, −I and –II. An
ESCRT-interacting protein, ALIX, binds to the ESCR
TIII component CHMP4 and the G protein-coupled
membrane receptor PAR1, which, in turn, sorts PAR1
as a cargo to MVBs without requiring ubiquitylation.
Additionally, ALIX interacts with the PDZ scaffolding
protein syntenin, leading to syndecans binding to
CD63 as PDZ ligand cargos. Therefore, ALIX, synte-
nin, syndecan and CD63 can all be found in MVBs and
exosomes without requiring ubiquitination [27, 28].
ESCRT-independent pathways regulate the biogenesis
of tetraspanin-containing exosomes and require the
participation of lipids. Exosomes are targeted by several
proteins via tetraspanins or protein lipidation, involving a
glycosylphosphatidyl inositol anchor or saturated fatty acid
modifications. Exosomes contains high concentration of
tetraspanins with four different transmembrane domains,
each possessing a particular palmitoylation site. CD9,
CD63, CD37, CD81, CD82 (along with other tetraspanins)
are considered to be specific exosome biomarkers, since
they are found abundantly on the exosome surface [11].
During the maturation of reticulocytes, exosomes are tar-
geted with three glycosylphosphatidyl inositol-anchored
proteins, i.e., CD55, CD58, CD59, and the palmitoylated
protein Lyn. Proteins with these lipid modifications enter
the lipid rafts consisting of sphingomyelins, cholesterols
and ceramides in a selective manner. The lipid rafts
accumulate in the exosomal membranes [29, 30]. Cellular
exosome release has been reported to be up-regulated by
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HIV-1 viral infection, which immediately leads to ESCRT-
independent biogenesis of exosomes. Nef, a HIV-1 protein
anchored to lipid raft micro-domains, has been observed in
exosomes from human cells infected with this virus. Two
classical exosomal markers, tetraspanins CD63 and CD81
are also found in these exosomes, which have similar sizes
to classical exosomes [20, 30]. Exosomes derived from
many cell types start off as cargo-containing ILVs within
LEs or MVBs. The ESCRT complex, tetraspanins and lipid
rafts can all promote exosome biogenesis. Ubiquitinated
cargoes are clustered by the ESCRT-0 complex. Membrane
budding is mediated by the ESCRT-I and ESCRT-II com-
plexes, and the resulting vesicles are cleaved from the mem-
brane via the “molecular scissors” role of the ESCRT-III
complex. High amounts of sphingomyelin, cholesterol, and
ceramide are located within the membrane lipid rafts of
exosomes. Both endocytic and exocytic processes are asso-
ciated with the microdomains of highly fluid lipid rafts, and
exosome formation is depended on tetraspanin function.
Cargoes are selected for further exosome release by tetra-
spanin family proteins, which possess four transmembrane
domains. The ILVs of MVBs and exosomes are enriched
with tetraspanins. Moreover, extracellular exosome secre-
tion is promoted by Nef, a HIV-1-encoded protein [25].
Exosomal microRNAs and gliomas
Exosomal microRNAs
The miRNA genes in the mammalian genome are
located within both protein-encoding and non-coding
DNA sequences [31]. The RNA polymerase II enzyme
transcribes the majority of miRNAs to initially pro-
duce long primary miRNAs (pri-miRNAs), and then
Fig. 1 A schematic of exosome formation. Exosome formation is divided into two main pathways: ‘classical’ and ‘direct’. The ‘direct pathway’
involves exosome formation via direct exocytosis of vesicles, such as MVs originating from the external budding of the plasma membrane. The
‘classical pathway’ requires the re-activation of endosomes that originated from the internal budding of the plasma membrane. This pathway
results in MVE. Following the active packaging of their components, MVE can fuse with the plasma membrane, and exosomes will then be
released to the extracellular space. Exosomes are composed of a lipid bilayer and contain non-coding miRNAs, transmembrane and cytoplasmic
proteins, and single-stranded and double-stranded DNA sequences. Exosomes contain proteins such as tetraspanins, ALIX, class-I and -II MHC
molecules, and tumor-derived neo-antigens. ALIX: ALG-2 interacting protein X; ESCRT: Endosomal sorting complexes required for transport; LE/
MVB: late endosome/multivesicular body; ILV: Intralumenal vesicle; MHC: Major histocompatibility complex; MVE: multi-vesicular endosomes; NEF:
Negative Regulatory Factor. Figure adapted from [25]
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the RNase III enzymes (Drosha and Dicer) continue the
process to create mature miRNAs consisting of 19–24
nucleotide duplexes (Fig. 2) [33]. Dicer transfers the
duplex to one of four Argonaute (Ago) proteins. The du-
plex has a guide strand with its 5′-U head region enriched
in A/G nucleotides. This 5′ sequence interacts with Ago
for the regulation of the expression of target mRNAs.
Furthermore, the duplex has a passenger strand that
usually starts with a 5′-C region, which is U/C rich and is
designed to be degraded. However, expression profiles in
several tissues have suggested that both strands could be
equally active [33]. There is an alternative pathway for
miRNA processing, which is Drosha-independent. This
pathway involves mirtrons (microRNAs located in the in-
trons of the mRNA encoding host genes), and snoRNA-
and tRNA-derived miRNAs.
Although some miRNAs can interact with Ago to
bind their target mRNA inside the cell, others must
be transported to MVBs via RNA-binding proteins
(RBPs) and finally loaded into exosomes and secreted
from the plasma membrane (Fig. 2 )[17]. Evaluation
of the exosomal miRNA profile derived from cardiac
fibroblasts showed high amounts of various miRNA
passenger strands [34]. The absence of Ago2 within
exosomes suggests that exosomal miRNAs are not
degraded and/or sorted by other RBPs [35].
Exosomal microRNAs and glioma resistance to drugs and
radiotherapy
Glioblastoma (GBM) has a poor prognosis because it
infiltrates and invades into the normal brain parenchyma
along vascular tracks. A combination of surgery and
radiotherapy and/or chemotherapy is the standard treat-
ment for GBM; unfortunately, cancer recurrence is most
commonly observed [36, 37]. Thus, it is necessary to
reverse GBM resistance to radiation and/or cytotoxic
Fig. 2 Biogenesis of exosomes within the parent cell and uptake of exosomes by the recipient cell. Vesicular pathways and miRNA/mRNA
pathways come together because some RNA molecules are bound within the endosomal limiting membrane in the cytoplasm. RBPs (RNA-
binding proteins) translocate miRNA strands into MVBs (multivesicular bodies) for exosome encapsulation, or to the cell membrane for further
release. During maturation, the endosomes are transported to the TGN (trans-Golgi network) where they either undergo lysosomal degradation
or secrete their intraluminal vesicles (ILVs) via microtubules towards the plasma membrane. Parent cell exosomes may carry out juxtacrine
signaling, fusion or endocytosis in order to interact with the recipient cells. Parent cells secrete microvesicles into the extracellular matrix, by
outward budding from the cell surface. Figure adapted from [32]
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drugs to find new approaches for treatment. Most solid
tumors grow in hypoxic conditions, which plays a vital
role in tumor development and resistance to treatment
by causing changes in the biology of both cancer and
stromal cells [38, 39]. Tumor hypoxia is one of the main
contributing factors to the failure of cancer treatment
[40], especially in radiotherapy.
Exosomal miRNAs are important in the development
of different types of cancer, including gliomas [41]. Yue
et al. showed that exosomal miR-301a contributed to
glioblastoma resistance to radiotherapy. Hypoxic GBM
cells secreted the exosomal miR-301a, which could be
transferred to responsive cells that were originally in
normoxic conditions, but then became resistant to radi-
ation. Exosomal miR-301a directly targeted TCEAL7 genes,
which function as tumor suppressors in GBM progression,
and actively suppressed their expression in normoxic
glioma cells. TCEAL7 down-regulated the Wnt/β-catenin
signaling pathway via inhibiting β-catenin translocation
from the cytoplasm to the nucleus. They suggested that the
Wnt/β-catenin pathway was triggered by miR-301a-
mediated suppression of TCEAL7. This recently discovered
exo-miR-301a/TCEAL7-signaling axis could be a new
target for reversing tumor cell resistance to radiotherapy in
GBM patients [42].
Temozolomide (TMZ) is a DNA-alkylating com-
pound that damages DNA and acts as a cytotoxic drug
against GBM. GBM can develop resistance to TMZ
thus lessening its effectiveness [43, 44]. TMZ creates
DNA double-strand breaks (DSBs) in DNA due to nu-
cleotide damage, which induce apoptosis by caspase-
dependent pathways [45, 46]. It has been demonstrated
that DSBs are often repaired via non-homologous end-
joining (NHEJ) [44, 46, 47]. The XRCC4 protein combines
with DNA ligase IV and forms a heterodimeric complex
that mediates the NHEJ process. This complex can join
together the broken ends of the DNA double strand and
help damaged cells survive [43, 44]. It has been reported
that the NHEJ pathway has a role in governing the sensi-
tivity of GBM cells to TMZ [44]. It has also been shown
that glioma sensitivity to TMZ is related to polymor-
phisms in the XRCC4 gene [48]. The expression of the
XRCC4 gene is considerably down-regulated in many
glioma cells, confirming the critical role of XRCC4 in
brain tumors [49]. However, more research is still needed
on the function of XRCC4 in the oncogenicity and TMZ
resistance in GBM.
Zeng et al. evaluated whether exosomal miRNAs could
contribute to TMZ-resistance in GBM cells [50]. The
expression level of miR-151a was measured using quantita-
tive PCR in two TMZ-resistant GBM cell lines. A RNA
chromatin immunoprecipitation (RNA-ChIP) assay, com-
bined with bioinformatics and microarray assays were used
to identify the main targets for miR-151a. The exosomes
isolated from cell lines, serum and cerebrospinal fluid
(CSF) were investigated, and their effects on resistance to
TMZ in target GBM cells were evaluated. A reduction in
miR-151a resulted in higher resistance to TMZ. Conversely
over expression of miR-151a sensitized chemo-resistant
GBM tumor cells to TMZ by suppressing the XRCC4-
DNA repair pathway. GBM chemo-resistant cells have a
lower content of miR-151a containing exosomes, which
induces resistance to TMZ. Restoration of the secretion of
miR-151a containing exosomes by the resistant cells
eliminated resistance to TMZ. Levels of miRNA-151a
containing exosomes in CSF reflected the chemo-resistance
of the GBM tumor. Therefore sampling of exosomal miR-
151a could act as a ‘liquid biopsy’ in a non-invasive manner
for evaluation of chemo-resistance. These exosomes could
also be a component of a treatment for refractory GBM
tumors [50].
Several reports have suggested that the miR-155HG/
miR-155 could have an important role in GBM develop-
ment, and that NSC141562 which acts as a miR-155/
miR-155 repressor, could be a part of GBM treatment
[51]. Shi et al. showed that miR-1238 could play a tumor
suppressor role in non-small cell lung cancer via target-
ing LHX2 and inhibiting proliferation [52]. Conversely,
Yin et al. showed that over-expression of miR-1238 plays
an important role in mediating the acquired TMZ resist-
ance in GBM patients [53]. Down-regulation of miR-
1238 in TMZ resistant cells could sensitize resistant
GBM cells by directly targeting the CAV1/EGFR path-
way. Bioactive miR-1238 present in exosomes shed from
TMZ-resistant cells could be taken up by TMZ-sensitive
cells, thus further spreading TMZ resistance [53]. It has
been reported that EGFR has a critical role in resistance
to TMZ [54, 55]. A combination of TMZ plus erlotinib
(an EGFR kinase inhibitor) could increase survival in
GBM patients in comparison with TMZ alone [56].
Using co-immunoprecipitation and confocal microscopy,
it was found that EGFR and CAV1 have mutual interac-
tions [53]. The EGFR-PI3K-Akt-mTOR signaling path-
way could be activated due to lack of CAV1 binding,
resulting in GBM tumor cells developing resistance to
TMZ. Therefore exosomal miR-1238 could not only be
a prognostic biomarker for assessment of chemotherapy
treatment protocols, but could also be an ideal for a
novel GBM treatment [53, 57].
Exosomal microRNAs and other glioma-related processes
Metastasis plays a critical role in most cancer related
deaths [58]. GBM is one of the most lethal cancers
worldwide, but mainly spreads by local invasion into the
brain, rather than by distant metastasis. However GBM
metastasis into the human central nervous system can
occur, and it makes surgical removal even more difficult
[59]. Cells from advanced cancers can secrete exosomes
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containing onco-proteins, long non-coding RNAs or miR-
NAs, which all promote tumor development [60, 61].
Many factors such as signaling between various cells,
blood vessels, stroma, extracellular matrix and secreted
molecules play important roles in the tumorigenesis and
development of GBM [62]. There are controversies about
the role of exosomes in GBM development. Recently, one
study showed that miR-5096 could stimulate the produc-
tion of filamentous pseudopodia and increase the invasive-
ness of glioma cells, through the regulation of the K+
channel Kir4.1. miR-5096 could also increase the release
of exosomes resulting in GBM metastasis [63].
The Cancer Genome Atlas (TCGA) has suggested that
miR-148a may increase the risk of GBM development
[64]. Cell adhesion molecule 1 (CADM1) is a neural
tissue-specific protein which plays a vital role in cell-cell
adhesion between identical and non-identical cells based
on the Ca2+ concentration [65]. It has been found that
CADM1 is a tumor suppressor factor and its expression
is suppressed in GBM tumor cells. The CADM1 pro-
moter was hypermethylated in the T98G GBM cell line
[66]. CADM1 could suppress activation of STAT3
signaling through interaction with HER2 and Itgα6β4
[67]. STAT3 signaling is commonly activated in GBM
cells, and suppression of STAT3 phosphorylation could
significantly reduce metastasis [68, 69]. Since the STAT3
pathway could stimulate metastasis and progression in
GBM cells, miR-148a could accelerate the progression of
GBM by increasing CADM1/STAT3 signaling [70, 71].
Cai et al., found that the levels of miR-148a contained in
exosomes in body fluids of GBM patients was higher
than healthy individuals [72]. In the T98G cell line, sup-
pression of miR-148a expression resulted in inhibition of
cancer development and metastasis. Furthermore, they
found that CADM1 could be a target for miR-148a,
according to results from a luciferase reporter assay. A
reduction was shown for mRNA and protein amounts of
CADM1 in GBM tumor tissues. Down-regulation of
CADM1 expression in GBM patient samples was closely
related to exosomal miR-148a. Furthermore, a miR-148a
antagonist activated STAT3 signaling through an in-
crease in the STAT3 protein concentration. Finally, they
found that miR-148a containing exosomes could stimu-
late tumor development and metastasis by activation of
STAT3 signaling via CADM1. They proposed that
exosomal miR-148a could be a prognostic factor or a
target for GBM treatment [72].
Myeloid-derived suppressor cells (MDSCs) are a diverse
population of naive myeloid cells that are characterized by
the CD11b +Gr-1+ phenotype in mice, and the CD14 +
HLA-DRlow/−phenotype in humans. MDSCs are pro-
duced in the bone marrow and are derived from myeloid
progenitor cells, and functional MDSCs carry out robust
inhibition of T cell function. Their immunosuppressive
function is linked to their ability to generate high amounts
of arginase-1, nitric oxide (NO), reactive oxygen species
(ROS) and to release IL-10 and transforming growth factor
β (TGF-β) [73]. The differentiation and function of MDSCs
is governed by activation signals, because the immunosup-
pressive type of MDSCs is found in cancerous mice but
not in healthy mice [73, 74]. Guo et al., identified that
glioma cells in a hypoxic condition can secrete miR-29a
and miR-92a containing exosomes, which induce the
differentiation of functional MDSCs [75]. They reported
that glioma-derived exosomes (GEXs) could increase active
MDSC differentiation both in vitro and in vivo. Further-
more, hypoxia-induced GEXs (H-GEXs) induced MDSCs
more strongly than normoxia-induced GEXs (N-GEXs). A
miRNA sequencing study of N-GEXs and H-GEXs,
showed that miR-29a and miR-92a containing exosomes
which were secreted under hypoxic conditions could
induce the proliferation of MDSCs. miR-29a and miR-92a
induced the propagation and activation of MDSCs by a
direct effect on high-mobility group box transcription
factor 1 (Hbp1) and the protein kinase cAMP-dependent
type I regulatory subunit alpha (Prkar1a). It was found that
gliomas secreted miRNA containing exosomes which
induced an immunosuppressive condition in the tumor
microenvironment, and that miR-29a/miR-92a containing
exosomes could exert regulatory effects on the function of
MDSCs [75].
miR-21 is a well-known miRNA that is up-regulated in
nearly all cancer types, and stimulates tumor cell prolif-
eration, invasion and metastasis. PDCD4, TIMP3, and
RECK are important regulators for apoptosis and metas-
tasis, are also targets for miR-21 [76–82]. Because miR-
21 is well-known for stimulating tumorigenesis, it has
been considered to be an interesting target for GBM
treatment. Suppression of miR-21 by various approaches
has been shown to increase apoptosis, radio−/chemo-
sensitivity, and to reduce tumor proliferation [83–87]. It
was found that miRNA suppression (via either a decoy
or a sponge molecule) could be useful for cancer treat-
ment. The sponge-shaped molecule could interact with
miRNA(s) or their originating sequences, and could
hinder the binding of the miRNA to mRNA [88–90].
Monfared et al., studied whether down-regulation of
miR-21 could affect U87-MG and C6 glioma tumor cell
lines. They engineered exosomes by loading them with a
molecule that sponged miR-21, and then added them to
the cells [91]. Their results showed that the engineered
exosomes could down-regulate miR-21, and conse-
quently PDCD4 and RECK which are the miR-21 targets
were over-expressed. Cells that were treated by sponge-
loaded exosomes showed a decrease in proliferation and
also increased apoptosis. Lastly, the miR-21-sponge
construct loaded into exosomes induced a significant
decrease in tumor volume in a rat model of GBM. Taken
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together, the results showed that administration of engi-
neered exosomes containing miR-21-sponge constructs
could be a novel treatment for GMB [91].
Exosomal microRNAs derived from mesenchymal stem
cells in glioma
Researchers have found that mesenchymal stem cells
(MSCs) play a vital role in tumor progression and devel-
opment [92]. Furthermore, bone marrow-derived adult
human mesenchymal stem cells (hMSCs) can differenti-
ate into various mesenchymal cell types [93]. Addition-
ally, some studies have suggested that MSCs could be
beneficial for GBM treatment [94]. Moreover, stem cells
have a high capacity to secrete exosomes. The released
exosomes can act as biomarkers of the paracrine secre-
tion of diverse factors produced by MSCs [95]. miR-
133b has been shown to play a tumor suppressor role in
many cancers [96]. Furthermore, miR-133b also acts as
an inhibitor for GBM [97]. Li et al., found that miR-
133b was involved in glioma growth and metastasis by
its regulatory effect on Sirt1 gene expression [98]. It was
shown that EZH2 is present in many different organisms
and is over-expressed in various types of cancer [99].
Abnormal up-regulation of the EZH2 gene in glioma
cells induces invasion and metastasis in GBM [100].
Furthermore, down-regulation of EZH2 suppresses
glioma growth through a negative regulatory effect on
the β-catenin signaling pathway [101]. The Wnt/β-ca-
tenin pathway is involved in the growth of the central
nervous system, and acts as a tumor-promoting pathway
in some cancers [102] and is also involved in GBM
development [103]. Xu et al., studied the effects of MSC-
derived exosomal miR-133b on glioma cell behavior
[104]. Microarray assays revealed differentially expressed
genes within glioma cells. miR-133b was down-regulated
and EZH2 was simultaneously up-regulated, leading to
the conclusion that EZH2 is down-regulated by miR-
133b. MSC-derived exosomal miR-133b suppressed
EZH2, and inhibited the development, invasion, and
metastasis of GBM by affecting the Wnt/β-catenin path-
way. Additionally, in vivo studies verified the ability of
MSC-derived exosomes loaded with miR-133b to inhibit
glioma tumor growth. Finally, MSC-derived exosomal
miR-133b and the Wnt/β-catenin/EZH2 pathway could
act as biomarkers for monitoring and prognosis in
glioma therapy [104].
The ADP-ribosylation factor GTPase-activating protein
(Arf GAP) catalyzes the hydrolysis of GTP by binding to Arf
(a GTP-binding protein of the Ras superfamily), which is
followed by alterations in various cellular functions [105].
Arf GAPs have a critical role in membrane vesicle formation
through facilitating the transportation of molecules between
different cellular organelles [106]. Arf GTPase-activating
protein-2 (AGAP2) mediates endosome trafficking and has
been shown to be up-regulated in various cancers [107]. Yu
et al., showed that MSC-derived exosomal miR-199a could
suppress glioma proliferation via decreasing the expression
of ArfGAP (which possesses a GTPase domain), an ankyrin
repeat and a PH domain 2 (AGAP2) [108]. The expression
levels of miR-199a and AGAP2 in glioma cells were evalu-
ated using qPCR, immunohistochemistry and Western blot-
ting. A miR-199a mimic transfected into MSCs, and their
secreted exosomes were added to U251 cells. The biological
function and chemo-sensitivity of U251 cells were evaluated
to study the role of miR-199a/AGAP2 in glioma. miR-199a
was down-regulated and AGAP2 was up-regulated in
glioma cells. MSC-derived exosomal miR-199a suppressed
development, invasion and metastasis in recipient glioma
cells. Moreover, addition of MSC-exosomal miR-199a
increased glioma cell sensitivity to TMZ, and inhibited
tumor growth in vivo, by exerting a negative regulative effect
on AGAP2 expression [108].
miR-584 is another tumor suppressor which can in-
hibit cancer cell proliferation, invasion and migration. It
was found that miRNA-584 down-regulates several on-
cogenes. Furthermore, miRNA-584 can induce apoptosis
via inhibiting gene expression of anti-apoptotic proteins
[109–112]. miR-584 affects the expression of CYP2J2,
which is related to the development of metastasis. A
study by Kim et al. specifically analyzed the role of miR-
584 in the progression of glioma [113]. They studied this
phenomenon by adding miRNA-containing exosomes to
the media of cultured MSCs, which had been transfected
by a miRNA mimic. This study evaluated the prolifera-
tion and invasion of tumor cells in vitro, and quantified
the expression of proteins that related to apoptosis,
growth, and metastasis. They carried out in vivo experi-
ments, in which U87 tumor cells which had been
exposed to miRNA-584-5p transfected MSC derived
exosomes were inoculated into mice. The aim of this
study was to confirm the ability of miRNA containing
exosomes to inhibit the progression of glioma tumors.
The results suggested that miRNA transfected MSCs-
derived exosomes could be a novel treatment approach
for glioma [113].
Exosomal microRNAs as biomarkers in glioma
The assessment and monitoring of the response to
glioma treatment in the neuro-oncology field remains
challenging [114]. Radiography and neuro-imaging
methods are not sensitive enough to detect the early
stages of tumor recurrence or progression. Furthermore,
distinguishing pseudo-progression and pseudo-responses
from their real counterparts is challenging. Histological
analysis of brain biopsy samples can absolutely diagnose
and evaluate tumor development, but numerous and
repeated brain biopsies are not desirable due to surgical
considerations. Moreover, biopsy specimens may not
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fully represent all the GBM cells that are present with
their genetic diversity. Improved non-invasive evaluation
of tumors would be a critical step to improve care for
GBM patients. More reliable biomarkers are required to
monitor treatment progress in a safe, accurate, and
time-saving manner before clinical symptoms become
apparent. The term “liquid biopsy” refers to a novel
approach to assess the GBM tumor burden, and monitor
the response to therapy. If this type of test could be
developed in the future, it could be an alternative to
common diagnostic procedures.
Exosomes are starting to be investigated as sources of
biomarkers that can be non-invasively obtained, and can
be used for the diagnosis and follow up of many
diseases, including cancer [115]. GBM-secreted exo-
somes are wide-spread in some body fluids and could be
sources for identifying nucleic acids and other cancer-
related biomarkers [116]. The protein and nucleic acid
expression profiles of GBM-derived exosomes have been
investigated [117, 118]. Both the exosomal miRNAs
(Table 1) and proteins (Table 2) could have important
role in glioma. Studies indicated that GBM-derived
exosomes contained many small non-coding RNAs
(sncRNAs) [168]. sncRNA sequencing showed that some
novel sncRNAs were present in GBM-derived exosomes
[168]. Studies have shown that some miRNAs, such as
miR-9 [119], miR-10a and miR-2 1[120], miR-222 and
miR-124-3p [121], miR-125b [122], mir-2 1[123], miR-
124a [124], miR-451 and miR-2 1[125], miR-22 1[126],
miR-103 and miR-125 [127], miR-302-367 [128], miR-
1290 and miR-1246 [129] were up-regulated, but other
miRNAs, such as miR-1587 [130], miR-375 [131], miR-
454-3p [132], miR-1246 [134], miR-146b [133], and
miR-124 [135] were down-regulated in glioma tumors
(Table 1). Although the miRNA content of GBM-
derived exosomes is related to the source cell, there is
likely to be a unique exosomal miRNA profile.
In one study, miRNA-containing exosomes were iso-
lated from the sera of GBM (n = 12) patients, and their
nucleic acid contents were sequenced [136]. Results
from the specimens from grade II-III (n = 10) glioma
patients were compared to healthy controls, which were
age- and gender-matched to patients. Significant differ-
ences were found in miRNA expression levels, and the
predictive power of individual miRNAs and subsets of
miRNAs was assayed by univariate and multivariate
statistical analyses. Further analysis based on specimens
from GBM patients (n = 4) and independent sets of
samples from healthy individuals (n = 9) and non-glioma
cancer patients (n = 10) as controls, were analyzed to
measure the specificity and predictive power of this
miRNA-based diagnostic assay. In total, 26 different
miRNAs were detected in exosomes extracted from sera
obtained from GBM patients compared to healthy
controls. Seven miRNAs (miR-182-5p, miR-328-3p,
miR-339-5p, miR-340-5p, miR-485-3p, miR-486-5p, and
miR-543) were chosen as the most stable candidates for
detecting GBM, according to random forest modeling
and data partitioning. Based on the aforementioned
studies, the measurement of six individual miRNA
sequences could discriminate GBM patients from
healthy controls with the required precision. Seven
miRNA biomarkers were able to properly identify all the
positive specimens in validation cohorts (n = 23). More-
over, 23 dysregulated miRNAs were found in samples of
IDHMUT, a lower-grade glioma. miRNAs detected in
serum could be used to diagnose GBM with greater
precision. It was found that exosomal miRNA profiles
are different from formerly described “free-circulating”
miRNAs in GBM patients, and appear to be superior for
diagnostic purposes [136].
Lan et al., reported that exosomes containing miR-
301a, which were isolated from patients with grade IV
GBM, were biologically active. They showed that the
proliferation and invasion of H4 glioma cells were
increased by addition of miR-301a exosomes [137]. The
study also found that exosomal miR-301a was over-
expressed in the sera of glioma patients in comparison
with healthy individuals. The elevated levels of miR-301a
containing exosomes were related to increased tumor
grade and lower Karnofsky performance status scores.
The levels of miR-301a containing exosomes in the
serum were significantly decreased after surgery of the
primary tumor, and were elevated again after GBM re-
lapse. Kaplan-Meier statistical analysis of tumor grade
(III or IV) in patients with elevated amounts of the miR-
301a containing exosomes in the serum showed a
shorter overall survival (OS) time in comparison with
patients with a lower level (p < 0.01). Univariate and
multivariate Cox regression analyses verified that the
amounts of miR-301a containing exosomes in the serum
were individually related to OS. Lastly, they concluded
that miR-301a could trigger AKT and FAK signaling
through a negative regulatory effect on PTEN. The study
showed that serum levels of exosomal miR-301a could
indicate variations in glioma patients. The miR-301a
containing exosomes in the serum could be an efficient
biomarker for GBM diagnosis and prognosis [137].
Manterola et al., [169] isolated exosomes from the sera
of 30 patients with GBM and 30 healthy controls. miR-
564-3p, miR-320 and RUN6–1 showed the largest
variation in expression based on miRNA chip technol-
ogy, and it was found that RUN6–1 (alone or with other
miRNAs) could be used for the diagnosis of GBM. Their
study also verified that cancer related miRNAs in serum
exosomes could act as biomarkers for the prognosis and
monitoring of CNS cancers [170]. Wei et al., [171] uti-
lized a quantitative analysis to determine the exosomal
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miR-301a Up TCEAL7 TCEAL7 is a tumor suppressor in GBM. TCEAL7 is able to modulate the
Wnt/β-catenin pathway by blocking β-catenin translocation from the
cytoplasm to the nucleus.
[42]
miR-151a Up XRCC4 miR-151a reduces XRCC4 levels, induces delay of DSB clearance and
encourages cells to become sensitive to TMZ.
[50]
miR-1238 Up CAV1 The loss of miR-1238 can sensitize resistant GBM cells by directly
targeting the CAV1/EGFR pathway.
[53]
mir-5096 Down Kir4.1, AQP-4 miR-5096 was down-regulated in gliomas. [63]
miR-148a Down CADM1 miR-148a promotes proliferation and metastasis via targeting CADM1
to activate the STAT3 pathway.
[72]
miR-29a Up Hbp1 miR-29a was up-regulated in gliomas. [75]
miR-92a Up Prkar1a miR-92a was up-regulated in gliomas. [75]
miR-133b Down EZH2 miR-133b represses proliferation, invasion, and migration by inhibiting
EZH2 and the Wnt/β-catenin signaling pathway.
[104]
miR-199a Down AGAP2 miR-199a inhibits glioma progression by down-regulating AGAP2 [108]
miRNA-584-5p Up CYP2J2 miRNA-584-5p reduces proliferation and invasion of glioma cells. [113]
miR-9 Up COL18A1, THBS2,
PTCH1 and PHD3
miR-9 increases angiogenesis. [119]
miR-10a and miR-21 Up RORA, PTEN The hypoxia-inducible expression of miR-10a and miR-21 in GDEs
mediates MDSC expansion and activation by targeting RAR-related





Up – miR-21, miR-222 and miR-124-3p were up-regulated in gliomas. [121]
miR-125b Up – miR-125b was up-regulated in gliomas [122]
mir-21 Up VEGF mir-21 was up-regulated in gliomas [123]
miR-124a Up FOXA2 miR-124a acts by silencing FOXA2, resulting in aberrant intracellular
lipid accumulation
[124]
miR-451, miR-21 Up c-Myc – [125]
miR-221 Up – miR-221 was up-regulated in gliomas. [126]
miR-21, miR-103,
miR-24, and miR-125
Up – miR-21, miR-103, miR-24, and miR-125 were up-regulated in gliomas. [127]
miR-302-367 Up CXCR4/SDF1, SHH,
cyclin D, cyclin A
and E2F1
Large amounts of miR-302-367 were found in exosomes, which were
internalized by neighboring GBM cells.
[128]
miR-1290, miR-1246 Up – miR-1290 and miR-1246 were up-regulated in gliomas. [129]
miR-1587 Down NCOR1 miR-1587 down-regulates the tumor-suppressive nuclear receptor
co-repressor NCOR1
[130]
miR-375 Down SLC31A1 miR-375 increases apoptosis while suppressing proliferation, migration
and invasion. Inhibits glioma cell progression through SLC31A1
suppression
[131]
miR-454-3p Down ATG12 miR-454-3p suppresses cell proliferation, migration, invasion, and
autophagy in glioma.
[132]
miR-146b Down EGFR and NF-κB miR-146b decreases EGFR and NF-κB protein in 9 L glioma cells
in vitro
[133]
miR-1246 Down TERF2IP miR-1246 activates the STAT3 signaling pathway and inhibits the
NF-κB signaling pathway.
[134]





Up – miR-328-3p, miR-339-5p, miR-340-5p, miR-485-3p,, and miR-543 were
up-regulated in gliomas.
[136]
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contents of GBM patients for the first time, and found
that the exosomes had a relatively abundant content of
miRNAs.
Li et al., assessed whether the measurement of miRNAs
could monitor the efficacy of radiotherapy in GBM
patients [172]. The miRNA contents of serum exosomes
were sequenced before and after radiotherapy in a cohort
study of GBM patients. The differentially expressed miR-
NAs, included 18 that were over-expressed and 16 that
were down-regulated. Consequently, the target genes of
the DE miRNAs were predicted based on various data-
bases. Moreover, it was shown that the target genes were
mainly involved in metabolism, the p53 pathway, and
tumor progression pathways, which suggested that these
miRNAs could play a vital role in the occurrence and
progression of glioma, via their effects on target genes.
Overall, the study found differences in the exosomal
miRNAs present in body fluids in response to radiother-
apy, and could be novel biomarkers to monitor the effects
of radiotherapy in glioma patients [138, 139, 172].
Exosomal proteins in glioma
Exosomal proteins have distinctive features compared to
other proteins that are employed as biomarkers. For
instance, nuclear transcription factor X-box-binding
protein 1 (NFX1) and cGMP-dependent protein kinase 1
(PKG1) have only been identified in serum exosomes
[173]. Some studies have suggested that H1° histone and
EGFRvIII that were transferred by exosomes could accel-
erate cancer development [174, 175]. On the contrary,
another study indicated that PTEN-containing exosomes
could inhibit GBM cell progression [176]. Tumor-
derived proteins that are freely circulating in blood may
be highly diluted, and could be mixed with other similar
circulating biomolecules, which could confuse the tests
[177, 178]. It was found that many exosomal proteins
such as HMGB 1[140], IL-8, PDGFs, caveolin 1, and
lysyl oxidase [141], L1CAM [142], STC1, STC2 [143],
EGFRvIII [144], VEGF-A [145], CRYAB [146], PTRF
[147], PD- 1[148], IL13Rα2, IL13QD [149], CAV 1[150],
NK-Exo [151], SRSF1, SRSF3 [152], NANOGP8 [153],
PTENP1 [155], CLIC1 [156], K-Ras [157], immuno-
globulin (Ig) G2 and IgG4 [158], TrkB [159], MGMT
mRNA [160], EGFRvIII [161], N-glycoproteins [162],
LOX, ADAMTS1, TSP1, VEGF [163], NF-κB [165],
Glut-1, HK-2, and PKM-2 [166], TDP-43 [167] were up-
regulated. On the other hand some other proteins, such
as IL-8, ZAP70, TGF-β [148], IFN-gamma, granzyme B
[154], and CRCL [164] were down-regulated in glioma
tumors (Table 2).
Secondly, exosomal proteins show a greater specificity
in comparison with free serum proteins. Glypican-1
(GPC1) which is abundant in the contents of tumor-
derived exosomes, showed higher specificity than serum
CA-199 or free GPC1 (100% vs. 79.49% vs. 82.14%) to
discriminate pancreatic tumor tissue from normal tissue
[179]. Thirdly, the encapsulation of proteins inside the
membrane of the exosomes make them generally more
stable than free proteins, because they are sheltered from
degradation by serum proteases and other enzymes [173].
Cell adhesion molecule L1CAM (L1, CD171) stimu-
lates the autocrine/paracrine secretion of various factors,
which stimulate the proliferation, migration and invasion
of glioma tumor cells. In normal tissue, L1 expression
plays a vital role in neuronal development where it is
located on the outer membrane of axons, but is also
expressed in glioma tumors [24, 180]. L1 possesses an
extracellular ectodomain, five fibronectin domains, and 6
immunoglobin-like domains, which are frequently de-
tached and released into the extracellular space. L1
undergoes interactions with different partner proteins,
such as L1 itself, integrins, and other outer membrane
proteins [181–183]. L1 has a molecular weight of 220
kDa and interacts with integrins through an arginine,
glycine, aspartic acid (RGD) domain [184, 185]. Two
types of integrins, which stimulate focal adhesion kinase
(FAK), and fibroblast growth factor receptor (FGFR)
were found to be interacting partners with L1 in glioma
tumors [186].
It was reported that L1 (or its ectodomain) that were
present in glioma cells could stimulate cell migration
[187–190]. Pace et al., showed that small exosomes with
L1 on the surface could stimulate glioma cell prolifera-
tion, migration, and invasion [142]. Exosomes with L1
on the surface were extracted from the media of the
T98G glioma cell line, and their effects on GBM cell







Down – miR-182-5p and miR-486-5p were down-regulated in gliomas. [136]
miR-301a Up PTEN miR-301a up-regulates PTEN. [137]
miR-221 Up DNM3 miR-221 up-regulates DNM3. [138]
miR-26a Up PTEN miR-26a increases proliferation and angiogenesis. [139]
Ghaemmaghami et al. Cell Communication and Signaling          (2020) 18:120 Page 10 of 19




HMGB1 Up SASH1 HMGB1 plays different roles depending on its location: as an extracellular
protein, HMGB1 decreases SASH1 expression, but as an exosomal protein,
HMGB1 increases SASH1 expression
[140]
IL-8, PDGFs, caveolin 1,
and lysyl oxidase
Up – The exosomal pathway constitutes a potential target that drives hypoxia-
dependent intercellular signaling during tumor development.
[141]
L1CAM Up FGFR, FAK Increases cell motility, proliferation, and invasiveness. [142]
STC1, STC2 Up – Induces cell migration in a hypoxia-dependent manner [143]
EGFRvIII Up CD44, BSG, CD151, CD81
and CD82
– [144]
VEGF-A Up claudin-5 and occluding Increases the permeability of the BBB in vitro by interrupting the
expression of claudin-5 and occludin.
In vivo permeability assay showed hypoxic GBM-derived exosomes
remained functional in the blood circulation and induced permeability in
the BBB.
[145]
CRYAB Up – The U373 glioma cells produce and secrete cryAB in exosomes;
stimulation with IL-1β and TNF-α significantly increased the levels of
cryAB not only in cells but also in secreted exosomes.
[146]
PTRF Up Cavin1 PTRF over-expression increases exosome secretion and induces cell
growth in vitro.
Clinical samples showed a positive correlation between tumor grade and
PTRF expression in both tumor tissue and exosomes isolated from blood
harvested from glioma patients.
[147]
PD-1 Up – – [148]
IL-8, ZAP70, TGF-β down ELISPOT, IL-13R, – [148]
IL13Rα2, IL13QD Up – Specific binding of IL13QD to tumor associated exosomes was confirmed. [149]
CAV1 Up p-ERK1/2 Exosome uptake appears to be dependent on intact ERK1/2-HSP27
signaling, and ERK1/2 phosphorylation was negatively influenced by CAV1
during internalization of exosomes.
[150]
NK-Exo Up CD63, Alix In vivo NK-Exo treatment inhibited tumor xenograft growth compared to
control mice, and pretreatment of mice with dextran sulfate 2 h before
NK-Exo treatment increased the antitumor effect of NK-Exo compared to
control and NK-Exo-alone-treated mice.
[151]
SRSF1, SRSF3 Up PTBP1,PTBP2 – [152]
NANOGP8 Up – – [153]
IFN-gamma, granzyme
B
Down – Granzyme B was significantly inhibited in CD8 + T cells exposed to GL26
cell-derived exosomes, and the exosomes could not inhibit the expression
of granzyme B in CD4 + T cells and NK cells.
[154]
PTENP1 Up miR-10a-5p The lncRNA PTENP1 could be packaged into exosomes from hUC-MSCs,
transferred to U87 cells, and then stabilized PTEN by competitively
binding miR-10a-5p.
[155]
CLIC1 Up GFP, FLAG-tagged CLIC1 is a circulating protein, secreted via extracellular vehicles (Evs)
released by either cell lines or GBM-derived CSCs.
[156]
K-Ras Up Raf-RBD – [157]
immunoglobulin (Ig)
G2 and IgG4
Up CD163 – [158]
TrkB Up YKL-40 Inhibits tumor growth in vivo.
Plays a key role in the control of GBM progression and aggressiveness.
[159]
MGMT mRNA Up – – [160]
EGFRvIII Up CD81 EGFRvIII expression either in exosomes or tissue was correlated with poor
survival.
[161]
N-glycoproteins Up Glycopeptide 329 N-glycosylation sites corresponding to 180 different N-glycoproteins
were enriched and identified in plasma exosomes of glioma patients and
healthy subjects.
[162]
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lines and primary GBM cells were studied. L1 expressing
exosomes increased the migration velocity in 3 cell lines
(T98G/shL1, U-118 MG, and primary GBM cells)
according to the highly sensitive SuperScratch assay in
comparison with L1-low expressing exosomes derived
from L1-attenuated T98G/shL1 cells. L1 expressing exo-
somes also increased proliferation based on cell cycle
analysis and cell counting. Furthermore, L1 expressing
exosomes caused primary glioma cell invasion in the
presence of the non-invasive T98G/shL1 cell line in a
chick embryo brain tumor model, but L1-low expressing
exosomes did not. The migration and cell proliferation
stimulated by L1, was reduced by inhibitors of focal
adhesion kinase (FAK) and FGFR, to different degrees.
Both L1 expressing exosomes as well as the soluble ecto-
domain of L1, could stimulate migration, proliferation
and invasion in glioma cells [142].
The SASH1 gene is commonly expressed in normal
tissue. The SASH1 protein is involved in cell growth,
proliferation, and apoptosis, and has been shown to play
a role in the progress of different diseases. SASH1 is
considered to be a tumor suppressor gene, because it is
absent or shows reduced function in many cancer types,
such as lung cancer [191], gastric cancer [192], colon
cancer [193, 194], cervical cancer [195], ovarian carcin-
oma [196], and thyroid cancer [197]. Previously, it was
found that SASH1 showed lower expression levels in
high-grade glioma tissue samples in comparison with
low-grade samples Reduced expression of SASH1 has
been correlated to poor prognosis [198]. Conversely, up-
regulated expression of SASH1 in GBM was correlated
with lower levels of proliferation and invasion [199].
Wu et al., reported that SASH1 gene knock-down in
cultured astrocytes considerably reduced cellular adhe-
sion and increased invasion [200]. Likewise SASH1 up-
regulation in the C6 cell line increased cell adhesion and
reduced invasion. Moreover, expression of the integrin
β8 was considerably lower in SASH1-down-regulated
astrocytes, and was increased in SASH1 over-expressing
C6 cells. In addition, DNA methylation and ChIP assays
indicated that the SASH1 gene was more methylated in
the C6 cell line than in astrocytes. Moreover, HMGB1 was
able to interact with the CpG islands in the SASH1 gene.
Up-regulation of HMGB1 in astrocytes caused hyper-
methylation of the SASH1 gene. This study showed that
HMGB1 was involved in SASH1 gene methylation, and
that methylation reduced the expression of the SASH1
and integrin β8 genes, resulting in decreased cell adhesion
and increased cell migration [200].
Ma et al., studied various protein expression patterns of
normal glial cell and glioma-derived exosomes, and the
effects of SASH1 gene expression in glioma [201]. They
isolated exosomes from astrocytes and C6 cells, and identi-
fied their exosomal proteins using mass spectrometry. The
results of gene ontology (GO) and Kyoto encyclopedia of
genes and genomes (KEGG) analysis showed that there
were various groups of unique proteins in exosomes from
normal glial cells and glioma cells. In normal cells, the chief
clusters were mostly involved with RNA transcription and
proteins, whereas in glioma cells the top clusters were
involved in activation of the PI3K-Akt pathway, adhesion,
and tumorigenesis pathways. Western blotting indicated
that although HMGB1 was present at a low level in
exosomes secreted from cultured astrocytes, it was signifi-
cantly up-regulated in the C6 cell line. Moreover, astrocyte-
derived exosomes could increase the expression of SASH1
in C6 cells, although the exosomes secreted from HMGB1-
low astrocytes could not. Recombinant HMGB1 caused
down-regulation of SASH1, while TLR4 expression was
enhanced. HMGB1 is an extracellular protein that normally
down-regulates SASH1, but when it is contained in exo-
somes it up-regulates SASH1. However, the aforemen-
tioned process, which was suggested to be related to TLR4
signaling, needs more research. The structure-dependent
function of the secreted protein HMGB1 to stimulate or
suppress tumorigenesis, opens a new horizon for under-
standing the interaction between tumor cells and their
microenvironment [201].
Hypoxia is an important factor that can disturb the integ-
rity of the blood-brain barrier (BBB). The BBB is composed
of specific brain microvascular endothelial cells (BMVECs)
that are joined together by tight junction complexes. The






Up KCNJ3 Induces differential gene expression in recipient glioma cells [163]
CRCL Down T cell Anti-tumor activity through modulating Cbl-b and c-Cbl signaling. [164]
NF-κB Up green fluorescent
protein
NF-κB inducible promoter mediates widespread reporter gene expression
in tumor-associated myeloid-derived cells after systemic injection of




Up MMP-2, MMP-9 Increases glucose consumption and generation of lactate and ATP. [166]
TDP-43 Up – – [167]
Ghaemmaghami et al. Cell Communication and Signaling          (2020) 18:120 Page 12 of 19
BBB acts to protect the microenvironment of the central
nervous system (CNS) from external toxins or infectious
pathogens. However, hypoxia disrupts the tight junctions of
the BBB. The disrupted tight junctions between the
BMVECs in GBM patients, results in the pathological
opening and outflow from the BBB [202–204]. How-
ever, the mechanism of BBB disruption in GBM pa-
tients has not been fully elucidated. Some studies have
shown that exosomes secreted from GBM cells contain
various pro-angiogenic factors that are needed for
proliferation and migration of endothelial cells [205].
Vascular endothelial growth factor (VEGF) is consid-
ered to be the best-known pro-angiogenic factor, and
was found to be present in GBM secreted exosomes,
although the role of exosomal VEGF in the BBB open-
ing is not fully understood [205, 206].
Zhao et al., showed that GBM-secreted exosomes
could induce the disruption of the BBB in laboratory
studies [145]. They found that the expression of VEGF-
A was up-regulated in GBM secreted exosomes in
hypoxic conditions, which increased the leakiness of an
in vitro BBB model via suppressing the expression of
claudin-5 and occluding proteins. An in vivo leakiness
assay indicated that the secreted exosomes from hypoxic
GBM tumors remained active during circulation, and
caused leakiness to develop in the BBB [145]. In CNS,
the protein known as cryAB/HspB5 (αB-crystallin or
small heat shock protein B5) is normally expressed in
astrocytes and oligodendrocytes [207]. In GBM, cryAB is
over-expressed in the brain [208, 209] and inhibits
apoptosis through binding and suppressing caspase-3
[208–210]. cryAB expression is up-regulated in various
neurodegenerative diseases including Parkinson’s dis-
ease, Alzheimer’s disease, multiple sclerosis, amyotrophic
lateral sclerosis, age-related macular degeneration and
traumatic brain injury, and is found to accumulate in as-
trocytes and oligodendrocytes of the CNS [211, 212].
cryAB has also been found in the extracellular matrix
adjoining retinal cells [213, 214], and it was also found
that presentation of cryAB epitopes could lead to stimu-
lation of T-cells [215, 216]. Both of these observations
suggested that cryAB was an important intracellular
protein in the CNS. It was then found that cryAB was
also a secreted protein, and it was further suggested that
exosomes could mediate its secretion [146, 213, 217–219].
Phosphorylation of cryAB mediated an interchange
between the monomeric and oligomeric states of the
protein, and affected its function [220–223]. Related to
secretion of cryAB by exosomes, a bioinformatics
analysis on its sequence using SecretomeP 2.0 [224] and
SignalP 4.1 [225] indicated that a signal peptide(s) were
required. Kore et al., found that the majority of the
cryAB molecules in exosomes were non-phosphorylated
[226]. Large cytosolic inclusion bodies were created after
transfection of cryAB-free glioma cells with a yellow
fluorescent protein (YFP)-tagged triple phosphomimic
(3-SD) cryAB construct. This study showed that phos-
phorylation considerably decreased the secretion of
cryAB in exosomes. Moreover, they found that inhib-
ition of the O-GlcNAcylation of cryAB also reduced its
co-localization with CD63 and Rab27, resulting in the
decreased secretion of exosomes. Hence, it was sug-
gested that O-GlcNAcylation and lack of phosphoryl-
ation were both involved in the loading and secretion
of cryAB in exosomes [226].
Conclusions
Exosomes play a vital role in glioma tumor biology,
immunology, and chemo-sensitivity and can act as
biomarkers for glioma diagnosis. The miRNAs and pro-
teins contained in exosomes have played a critical role
in diverse cancers, including glioma. The packing of
miRNAs into exosomes is a selective process. The levels
of individual miRNAs and proteins inside exosomes are
altered during tumorigenesis. Based on these data, the
miRNA and protein contents of exosomes could be used
as a new type of biomarker for the diagnosis and moni-
toring of treatment response of gliomas. Furthermore,
the diagnostic efficiency of the miRNA and protein con-
tents of exosomes could be superior to more commonly
employed biomarkers. Exosomes can transfer miRNAs
and proteins between tumor cells for the transmission of
information and to mediate signaling pathways. miRNA
and protein-containing exosomes can modulate tumor
progression and metastasis, and could likewise play a
critical role in the immune responsiveness and chemo-
sensitivity of tumors. Aberrant expression of exosomal
miRNAs and proteins has been reported in several can-
cers, including gliomas, and is implicated in glioma
pathogenesis and progression, suggesting their possible
application in diagnosis, prognosis and therapy. In this
review, the role of several exosomal miRNAs and proteins
that regulate various oncogenes and tumor suppressor
genes involved in glioma development, their prospective
roles as prognostic and diagnostic markers and their
therapeutic targets were summarized.
Furthermore, exosomes could be potentially used to
transfer chemotherapeutic drugs and biotherapeutic agents
to various cells and tissues. Thus, engineered exosomes
could play a future role as efficient delivery vehicles for
direct targeting of glioma tumor cells. Nowadays, TMZ and
cisplatin are often used for chemotherapy of glioma, but a
method to overcome the development of chemo-resistance
to these drugs is required, which may involve intervention
to modulate miRNAs and exosomes. More studies are
required to fully identify the specific miRNA and protein
contents of exosomes, and their mechanism of action in
various cancers, including gliomas.
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